UFPT
Ufp Technologies IncPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net income non-GAAP | $19.3M | the first quarter of 2026 | — |
| Adjusted operating income non-GAAP | $25.8M | the first quarter of 2026 | — |
|
|
|||
| adjusted earnings per diluted share non-GAAP | $2.48 | first quarter call | — |
| adjusted operating margin non-GAAP | 16.7% | first quarter call | — |
| leverage ratio | 1.14 | first quarter call | — |
| Adjusted EBITDA non-GAAP | $121.1M | year ended December 31, 2025 | — |
| Adjusted gross margin non-GAAP | 29.3% | year ended December 31, 2025 | — |
| Adjusted SG&A as a percentage of sales non-GAAP | 11.2% | year ended December 31, 2025 | — |
| Organic sales growth non-GAAP | 1.5% | year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UFPT
this stock
Ufp Technologies Inc
|
$1.99B | +10.8% | +19.5% | 29.1 | 17.3% |
|
ABT
Abbott Laboratories
|
$171.49B | -28.4% | +5.7% | 27.6 | 1.3% |
|
SYK
Stryker Corp
|
$126.90B | -9.7% | +11.2% | 38.3 | 1.8% |
|
MDT
Medtronic plc
|
$106.96B | -15.5% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.32B | -54.9% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UFPT | -2.2% | +5.6% | -7.3% | -7.2% | +10.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -3.5% | +5.8% | -17.4% | -8.3% | +0.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.